CONFERENCE PROGRAM

TUESDAY, FEBRUARY 16

5:00 p.m.-7:30 p.m. Welcome and Keynote Lectures

Monarchy Ballroom

Session Chairpersons: Tetsuo Noda, Japanese Foundation for Cancer Research Cancer Institute, Tokyo, Japan, and Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA

PD-1 blockade in cancer treatment: Precision medicine meets immunotherapy*

Suzanne L. Topalian, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA

Development of novel anti-cancer drugs targeting cancer stem cells*

Yusuke Nakamura, The University of Chicago, Chicago, Illinois, USA

7:30 p.m.-9:00 p.m. Opening Reception

Napoli Gardens

WEDNESDAY, FEBRUARY 17

7:00 a.m.-8:00 a.m. Continental Breakfast

Sunset Terrace

8:00 a.m.-9:30 a.m. Plenary Session 1: Cancer Genomes

Monarchy Ballroom

Session Chairpersons: Hitoshi Nakagama, National Cancer Center, Tokyo, Japan, and Alan D'Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Integrated Molecular analysis of adult T-cell leukemia and lymphoma*

Seishi Ogawa, Kyoto University, Kyoto, Japan

Therapy of lymphoma inspired by functional and structual genomics

Louis M. Staudt, National Cancer Institute, Bethesda, Maryland, USA

Clonal evolution in T-cell lymphoma: Tumor cells and beyond*

Mamiko Sakata-Yanagimoto, University of Tsukuba, Tsukuba, Japan

9:30 a.m.-10:00 a.m. Coffee Break

Sunset Terrace

^{*}An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.

10:00 a.m.-11:30 a.m. Plenary Session 2: DNA Damage and Repair

Monarchy Ballroom

Session Chairpersons: Fuyuki Ishikawa, Kyoto University, Kyoto, Japan, and Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Cellular senescence as an anti-cancer barrier

Makoto Nakanishi, Nagoya City University, Nagoya, Japan

Targeting DNA repair in cancer therapy*

Alan D. D'Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

RNF8 regulates interstrand crosslink repair of BRCA1-53BP1 knockout cells*

Shinichiro Nakada, Osaka University, Osaka, Japan

11:30 a.m.-4:00 p.m. Free Time

4:00 p.m.-5:30 p.m. Plenary Session 3: Therapies Based on Signal Transduction

Monarchy Ballroom

Session Chairpersons: Masaki Mori, Osaka University, Osaka, Japan, and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Identification of novel driver targets in human cancer*

Hiroyuki Mano, The University of Tokyo, Tokyo, Japan

A vulnerability of drug resistant melanomas with therapeutic implications*

René Bernards, Netherlands Cancer Institute, Amsterdam, The Netherlands

Mechanisms for fine-tuning of apoptosis signal-regulating kinase 1 (ASK1) by ubiquitin-related enzymes*

Atsushi Matsuzawa, Tohoku University, Sendai, Japan

5:30 p.m.-7:30 p.m. Poster Session A

Regency Ballroom

THURSDAY, FEBRUARY 18

7:00 a.m.-8:00 a.m. Continental Breakfast

Sunset Terrace

8:00 a.m.-9:30 a.m. Plenary Session 4: Epigenetics

Monarchy Ballroom

Session Chairpersons: Takuro Nakamura, The Cancer Institute of JFCR, Tokyo, Japan, and Louis M. Staudt, National Cancer Institute, Bethesda, Maryland, USA

Genomic and epigenomic profiles of Asian-endemic cancers*

Patrick B. Tan, Duke-NUS Graduate Medical School Singapore/Genome Institute of Singapore, Singapore

Title to be announced

Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Dissecting the cancer epigenome with iPS cell technology*

Yasuhiro Yamada, Kyoto University, Kyoto, Japan

^{*}An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

9:30 a.m.-10:00 a.m. Coffee Break

Sunset Terrace

10:00 a.m.-11:30 a.m. Plenary Session 5: Tumor Microenvironment

Monarchy Ballroom

Session Chairpersons: René Bernards, Netherlands Cancer Institute, Amsterdam, The Netherlands, and Motoharu Seiki, Kanazawa University, Ishikawa, Japan

Procarcinogenic bacteria and procarcinogenic immune responses: The microbial approach to cancer screening and prevention

Drew M. Pardoll, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA

Diverse molecular targeting of tumor vasculatures*

Gou Young Koh, KAIST, Daejeon, South Korea

Lymphatic vessels regulate the immune microenvironment in melanoma*

Amanda W. Lund, Oregon Health & Science University, Portland, Oregon, USA

11:30 a.m.-4:30 p.m. Free Time

4:30 p.m.-5:30 p.m. Plenary Session 6: Cancer Metabolism

Monarchy Ballroom

Session Chairpersons: Atsushi Ochiai, National Cancer Center Research Institute, Kashiwa, Japan, and Ernest T. Hawk, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

The Keap1-Nrf2 system in cancer development

Masayuki Yamamoto, Tohoku University, Sendai, Japan

Dealing with hunger: How cancer cells adapt to glutamine deprivation*

Mei Kong, City of Hope Beckman Research Institute, Duarte, California, USA

5:30 p.m.-7:30 p.m. Poster Session B

Regency Ballroom

FRIDAY, FEBRUARY 19

7:00 a.m.-8:00 a.m. Continental Breakfast

Sunset Terrace

8:00 a.m.-9:30 a.m. Plenary Session 7: Cancer Prevention and Molecular Epidemiology

Monarchy Ballroom

Session Chairpersons: Drew M. Pardoll, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA, and

Masanori Hatakeyama, The University of Tokyo, Tokyo, Japan

^{*}An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

Cancer prevention as an urgent priority: Driving progress through molecular and translational research as well as population-based actions*

Ernest T. Hawk, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Obesity and cancer: A gut microbial connection*

Eiji Hara, Osaka University, Osaka, Japan

A novel radiogenomic approach may improve prediction of malignant pathology in patients with intraductal papillary mucinous neoplasms of the pancreas*

Jennifer B. Permuth, Moffitt Cancer Center, Tampa, Florida, USA

9:30 a.m.-10:00 a.m. Coffee Break

Sunset Terrace

10:00 a.m.-11:30 a.m. Plenary Session 8: Non-coding RNAs

Monarchy Ballroom

Session Chairpersons: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA, and Takashi Takahashi, Nagoya University Graduate School of Medicine, Nagoya, Japan

Causes and consequences of microRNA dysregulation in cancer*

Carlo M. Croce, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA

Extracellular vesicles as a novel diagnostic and therapeutic target for cancer*

Takahiro Ochiya, National Cancer Center Research Institute, Tokyo, Japan

Molecular mechanism underlying stable X-chromosome inactivation to prevent cancer pathogenesis*

Yuya Ogawa, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

11:30 a.m.-4:00 p.m. Free Time

4:00 p.m.-5:30 p.m. Plenary Session 9: Cancer Immunotherapy

Monarchy Ballroom

Session Chairpersons: Suzanne L. Topalian, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA, and Toshihiko Torigoe, Sapporo Medical University, Sapporo, Japan

Engineering T cells to effectively target tumors

Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Targeting regulatory T cells for cancer immunotherapy*

Shimon Sakaguchi, Osaka University, Osaka, Japan

Talk title to be announced

Russell K. Pachynski, Washington University School of Medicine, St. Louis, Missouri

5:30 p.m.-7:30 p.m. Poster Session C

Regency Ballroom

^{*}An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.

SATURDAY, FEBRUARY 20

7:00 a.m.-8:00 a.m. Continental Breakfast

Sunset Terrace

8:00 a.m.-9:30 a.m. Plenary Session 10: Stemness and Metastasis

Monarchy Ballroom

Session Chairpersons: Yoshinori Murakami, The University of Tokyo, Tokyo, Japan, and Carlo M. Croce, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA

Invasive intestinal cancer by TGF-β **suppression in an inflammatory microenvironment** Masanobu Oshima, Cancer Research Institute, Kanazawa University, Kanazawa, Japan

Targeting Nodal signaling to suppress tumor cell plasticity and aggressiveness*Mary J.C. Hendrix, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA

Dissecting leukemia initiation and creating therapeutic strategies in FLT3-ITD+ human acute myeloid leukemia*

Fumihiko Ishikawa, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan

9:30 a.m.-10:00 a.m. Coffee Break

Sunset Terrace

10:00 a.m.-12:00 p.m. Plenary Session 11: Drug Resistance and Molecularly Targeted Therapies

Monarchy Ballroom

Session Chairpersons: Julian Downward, Francis Crick Institute, London, United Kingdom, and Naoya Fujita, The Cancer Institute of JFCR, Tokyo, Japan

Endocrine resistance in ER+breast cancer: Mechanisms and therapeutic combinations

Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA

Novel strategy for overcoming EGFR-TKI resistance in EGFR mutant lung cancer*

Seiji Yano, Kanazawa University, Kanazawa, Japan

Targeted therapies to overcome drug resistance in myeloma*

Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Resistance mechanisms to tyrosine kinase inhibitors in fusion gene positive non-small cell lung cancer*

Ryohei Katayama, Japanese Foundation for Cancer Research, Tokyo, Japan

12:00 p.m.-4:00 p.m. Free Time

^{*}An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.

4:00 p.m.-5:30 p.m. Plenary Session 12: Early Detection and Circulating Tumor Cells

Monarchy Ballroom

Session Chairpersons: Mary J.C. Hendrix, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA, and Yoshio Miki, Tokyo Medical and Dental University, Tokyo, Japan

Early detection and targeting of RAS mutant cancer*

Julian Downward, Francis Crick Institute, London, United Kingdom

Rapid and sensitive imaging of tiny tumors by topically spraying novel fluorogenic probes for peptidases and glycosidases*

Yasuteru Urano, The University of Tokyo, Tokyo, Japan

Circulating tumor cells: A window into the metastatic cascade*

David T. Ting, Massachusetts General Hospital Cancer Center/Harvard Medical School, Charlestown, Massachusetts, USA

7:00 p.m.-7:30 p.m. Closing Reception

Grand Promenade

7:30 p.m.-9:30 p.m. Closing Banquet

Monarchy Ballroom

^{*}An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.